Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by Francine01on Feb 08, 2019 1:44pm
92 Views
Post# 29339015

RE:RE:ACST - NEWS OUT -2 dollar next week

RE:RE:ACST - NEWS OUT -2 dollar next weekHere are some thoughts for next week quarter release:

- Management forgot to press release the shares issuance on the bond $1.9M, (unless they paid in cash).

- I hope they will disclose full randomization and between 40-50% completed the trial.

- Timeframe for phase 3, last patient visit ; April, May or June ?

- Timeframe of when they will release results : September ?

- How they will expend production, do they have a plan to expend the production if Phase 3 is positive ?

- Update on the commercialisation, are they waiting trial results to maximise deal value, status of discussions, what is the plan for north america, china, etc ?

- 2019 is crucial, Acasti need to expend board team to more than 4 individuals. They need financial experts and scientists to support the management. 

Again, the market under estimate the potential of all the 22 secondary end points.

I hope to see SP around $3US by next summer and potential 8$-10$ following positive results. 

Good luck to all. 


Bullboard Posts